Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT04902053
Other study ID # 2017-12
Secondary ID
Status Suspended
Phase
First received
Last updated
Start date June 2028
Est. completion date January 2031

Study information

Verified date August 2023
Source Edwards Lifesciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of the INSPIRIS RESILIA Aortic Valve-in-valve (ViV) Surveillance Study ("the Study") is to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.


Description:

This is a single-arm observational study which includes both prospective and retrospective data. At least fifty (50) Subjects enrolled prospectively prior to the ViV procedure, or retrospectively after the ViV procedure (within 37 days post-ViV procedure) with dysfunctional 19mm-25mm INSPIRIS aortic valves, will participate in this study. All subjects will be followed for up to 1 month after the TAVR ViV procedure.


Recruitment information / eligibility

Status Suspended
Enrollment 50
Est. completion date January 2031
Est. primary completion date December 2030
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Subjects must meet all of the following Inclusion Criteria: 1. 18 years or older at the time of the TAVR ViV treatment 2. Has an INSPIRIS RESILIA aortic valve implanted in the aortic position confirmed to be size 19mm, 21mm, 23mm or 25mm 3. A ViV procedure using an Edwards transcatheter aortic heart valve (TAVR) has been scheduled; or completed within 37 days from time of consent 4. The participant agrees to attend a follow-up assessment at 1 month post ViV procedure 5. The participant provides written informed consent prior to the post-ViV procedure CT scan Exclusion Criteria: Subjects must not meet any of the following Exclusion Criteria: 1. The INSPIRIS RESILIA aortic valve size is - Unconfirmed, or - Confirmed to be 27mm or 29mm 2. Prior re-interventions have been performed on the INSPIRIS RESILIA aortic valve 3. The INSPIRIS RESILIA aortic valve has been subjected to balloon aortic valvuloplasty (BAV) prior to the baseline quantitative area measurement of the valve area 4. The Subject is pregnant or desires to become pregnant within 40 days of the ViV procedure 5. Subjects with a known contraindication or hypersensitivity to contrast media that cannot be adequately pre-medicated per hospital guidelines

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Subjects previously implanted with INSPIRIS RESILIA Model 11500A and are undergoing planned valve-in-valve treatment.
Designed to capture Adverse Event information and valve measurement data from dysfunctional INSPIRIS RESILIA aortic valves before and after Valve-in-valve (ViV) treatment.

Locations

Country Name City State
United States The Cleveland Clinic Foundation Cleveland Ohio
United States University of Florida Gainesville Florida
United States St. Vincent Hospital Indianapolis Indiana
United States University of Southern California Los Angeles California
United States Nyph/Cumc New York New York
United States AdventHealth Orlando Orlando Florida
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Edwards Lifesciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subject's Occurrence Rate of the Composite Safety Endpoint The primary safety endpoint is a composite endpoint defined as all-cause mortality, all stroke (disabling and non-disabling), life-threatening bleeding, new requirement for dialysis, coronary artery compression or obstruction, major vascular complication, and valve-related dysfunction requiring reintervention.
Data will be reported as the number (and percent) of subjects who experience an event divided by the number of enrolled subjects times 100.
Events occurring within 30 days of valve-in-valve procedure
Primary Subject's Occurrence Rate of Valve Malpositioning Valve malpositioning includes all instances of ViV-TAVR migration, embolization, and valve recapture or retrieval.
Data will be reported as the number (and percent) of subjects who experience an event divided by the number of enrolled subjects times 100.
Events occurring within 30 days of valve-in-valve procedure
Primary Subject's average INSPIRIS RESILIA Valve Expansion Post Valve in Valve Procedure Compared to Baseline A primary effectiveness endpoint is the average expansion, measured in mm, of INSPIRIS valve for sizes 19mm-25mm, following the Edwards transcatheter aortic valve implantation. Day 30, compared to baseline
Secondary Subject's Occurrence Rate of Reportable Adverse Events Reportable Adverse Events mirroring those being reported to the STS/ACC TVT Registry.
Data will be reported as the number (and percent) of subjects who experience an event divided by the number of enrolled subjects times 100.
Events occurring within 30 days of valve-in-valve procedure
See also
  Status Clinical Trial Phase
Completed NCT00774293 - Homoeopathic Association in Aortic Valve Surgery Phase 4
Completed NCT05107453 - Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery Phase 4
Completed NCT01651780 - Open-label, Randomized Trial in Patients Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH Phase 3
Completed NCT01187329 - The Effect of the Hyperinsulinemic Normoglycemic Clamp on Myocardial Function and Utilization of Glucose N/A
Recruiting NCT05295628 - Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR N/A
Terminated NCT03680040 - RESILIENCE Trial: Evaluation of the Durability of Aortic Bioprostheses/Valves With RESILIA Tissue in Subjects Under 65
Recruiting NCT05539937 - Prospective Evaluation of the Quality of Life of Elderly Patients Undergoing Transfemoral Percutanous Aortic Valve Replacement (TAVI) for the Treatment of Severe Aortic Stenosis.
Recruiting NCT01522352 - Comparison Between Three Types of Stented Pericardial Aortic Valves N/A
Completed NCT01554709 - Safety and Performance Study of the CardioGard Cannula Phase 2/Phase 3
Completed NCT01404975 - TAVI Protocol - Paravertebral Block Study N/A
Recruiting NCT03889288 - Innovative Device for Pain Management by Millimeter Band Radiation: Electronic-Pain Killer N/A
Active, not recruiting NCT05404880 - INSPIRIS China PMCF Study
Recruiting NCT04652375 - Outcomes After Albumin vs Lactated Ringer's Solution in CABG and AVR Procedures N/A
Recruiting NCT06106451 - Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study) N/A
Completed NCT00860730 - PERCEVAL Pivotal Trial N/A
Active, not recruiting NCT00396760 - Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery Phase 3
Not yet recruiting NCT03603483 - Aortic Root Enlargement in Aortic Valve Replacement N/A
Terminated NCT01368666 - Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark N/A
Recruiting NCT03002272 - Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study
Active, not recruiting NCT03258333 - Small Aortic Annulus - a New Solution to the Old Problem N/A